Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo Nordisk Q2 2018 sales disappoint

Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.

Read More »

Shire’s Sales Up Ahead of Takeda Acquisition

As Shire’s acquisition by Takeda Pharmaceutical approaches, the global biotechnology company reported a solid second-quarter 2018.

Read More »

Sanofi Q2 Report: Sales Down, But Company Has Plans To Fix Diabetes Division

Paris-based Sanofi reported a decrease in second-quarter 2018 net sales of 5.7 percent, down to 8.176 billion euros.

Read More »

Pfizer’s Q2 2018 Earnings Exceed Expectations

Pfizer Inc. reported solid second-quarter 2018 financial results, with total company revenues up two percent operationally.

Read More »

Roche Q2 2018 Financials: “Firing on All Cylinders”

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.

Read More »

Celgene Reports Double-Digit Growth For Q2 2018 Net Product Sales

Celgene Corporation reported net product sales of nearly $3.81 billion for the second quarter of 2018, a 17 percent increase from the same period in 2017.

Read More »

J&J Announces Binding Offer from Fortive to Acquire Advanced Sterilization Products

Johnson & Johnson received a binding offer to sell its Advanced Sterilization Products (ASP) business to Fortive Corporation. The deal is valued at $2.8 billion.

Read More »

Pharma Sales Drive J&J’s 2018 First Quarter

Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.

Read More »

Charles River Acquires Global CRO

Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.

Read More »

Gilead fourth-quarter hepatitis C drug sales plummet, sees further slowdown

Gilead Sciences Inc. said fourth-quarter 2017 sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for 2018.

Read More »

Allergan’s migraine drug succeeds in key study

Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.

Read More »

AstraZeneca Posts Disappointing 2017 Financials

AstraZeneca saw revenues and product sales fall over the course of 2017. Total revenues declined 2 percent to $22.46 billion and product sales fell 5 percent to $20.15 billion.

Read More »

Seattle Genetics Snaps Up Cascadian in $614 Million Buyout Deal

Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.

Read More »

Top 20 Life Science Startups to Watch in 2018

BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.

Read More »

Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion

Mallinckrodt plc will acquire Sucampo Pharmaceuticals Inc., including its commercial and development assets.

Read More »

Regeneron’s Q3 2017 profit tops Street view

Regeneron Pharmaceuticals reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for its flagship eye treatment Eylea and new eczema drug Dupixent.

Read More »

SEC Charges Osiris, Four Former Execs With Accounting Fraud

Osiris Therapeutics settled a case of accounting fraud with the U.S. SEC, but four former company executives will face charges for the alleged financial misreporting.

Read More »

Sanofi Falls Short of Q3 2017 Expectations

The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in third-quarter 2017.

Read More »

Pfizer beats Q3 2017 profit estimates

Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.

Read More »

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise

AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom